Pulmonx (NASDAQ:LUNG) Now Covered by Analysts at Lucid Cap Mkts

Pulmonx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Lucid Capital Markets initiated coverage of Pulmonx with a “strong-buy” rating. Across firms, the stock has a “Moderate Buy” consensus and an average price target of $7.50.
  • Pulmonx beat quarterly expectations, reporting a loss of $0.19 per share versus estimates of $0.26 and revenue of $22.84 million versus $21.93 million.
  • The shares opened at $2.74, within a 52-week range of $1.13 to $3.25; analysts forecast a full-year loss of $0.98 per share.
  • Five stocks we like better than Pulmonx.

Research analysts at Lucid Cap Mkts started coverage on shares of Pulmonx (NASDAQ:LUNG - Get Free Report) in a report issued on Wednesday, Zacks reports. The firm set a "strong-buy" rating on the stock.

Several other research firms have also recently weighed in on LUNG. Weiss Ratings cut shares of Pulmonx from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday. Stifel Nicolaus increased their price target on shares of Pulmonx from $2.50 to $4.00 and gave the company a "buy" rating in a research note on Wednesday, October 28th. Canaccord Genuity Group set a $5.00 target price on Pulmonx in a research note on Wednesday, October 28th. Finally, Loop Capital set a $7.00 price target on shares of Pulmonx in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pulmonx presently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Get Our Latest Analysis on Pulmonx

Pulmonx Price Performance

Pulmonx stock opened at $2.74 on Wednesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.31 and a current ratio of 4.05. The firm has a market cap of $119.33 million, a P/E ratio of -2.71 and a beta of 0.19. The business's fifty day moving average is $2.19 and its two-hundred day moving average is $1.73. Pulmonx has a 52 week low of $1.13 and a 52 week high of $3.25.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07. Pulmonx had a negative return on equity of 98.23% and a negative net margin of 47.93%. The company had revenue of $22.84 million during the quarter, compared to analyst estimates of $21.93 million. Equities research analysts forecast that Pulmonx will post -0.98 earnings per share for the current fiscal year.

Insider Activity

In other Pulmonx news, General Counsel David Lehman sold 14,334 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,394.84. Following the sale, the general counsel directly owned 361,827 shares of the company's stock, valued at approximately $817,729.02. This represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Srikanth Radhakrishnan sold 14,245 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $32,193.70. Following the completion of the sale, the insider directly owned 316,994 shares in the company, valued at approximately $716,406.44. The trade was a 4.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 78,340 shares of company stock worth $177,048 in the last quarter. Corporate insiders own 7.50% of the company's stock.

Hedge Funds Weigh In On Pulmonx

Institutional investors and hedge funds have recently modified their holdings of the stock. Parkman Healthcare Partners LLC acquired a new position in shares of Pulmonx in the second quarter valued at approximately $841,000. Stonepine Capital Management LLC acquired a new position in Pulmonx in the 2nd quarter valued at $1,060,067. BlackRock Inc. bought a new position in Pulmonx during the second quarter worth about $1,147,000. Deutsche Bank AG acquired a new stake in Pulmonx in the 2nd quarter worth about $523,000. Finally, ADAR1 Capital Management LLC bought a new stake in Pulmonx in the 2nd quarter valued at about $526,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

(Get Free Report)

Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company's Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.

Featured Stories

Analyst Recommendations for Pulmonx (NASDAQ:LUNG)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pulmonx Right Now?

Before you consider Pulmonx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.

While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines